GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » POINT Biopharma Global Inc (NAS:PNT) » Definitions » Tangible Book per Share

POINT Biopharma Global (POINT Biopharma Global) Tangible Book per Share : $4.01 (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is POINT Biopharma Global Tangible Book per Share?

Tangible book value per share is calculated as the total tangible equity divided by Shares Outstanding (EOP). Total tangible equity is calculated as the Total Stockholders Equity minus Preferred Stock minus Intangible Assets. POINT Biopharma Global's tangible book value per share for the quarter that ended in Sep. 2023 was $4.01.

Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


POINT Biopharma Global Tangible Book per Share Historical Data

The historical data trend for POINT Biopharma Global's Tangible Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

POINT Biopharma Global Tangible Book per Share Chart

POINT Biopharma Global Annual Data
Trend Dec20 Dec21 Dec22
Tangible Book per Share
0.15 2.83 4.61

POINT Biopharma Global Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Tangible Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.97 4.61 4.46 4.23 4.01

Competitive Comparison of POINT Biopharma Global's Tangible Book per Share

For the Biotechnology subindustry, POINT Biopharma Global's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


POINT Biopharma Global's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, POINT Biopharma Global's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where POINT Biopharma Global's Price-to-Tangible-Book falls into.



POINT Biopharma Global Tangible Book per Share Calculation

POINT Biopharma Global's Tangible Book Value Per Share for the fiscal year that ended in Dec. 2022 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(486.954-0-0)/105.65
=4.61

POINT Biopharma Global's Tangible Book Value Per Share for the quarter that ended in Sep. 2023 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(424.192-0-0)/105.766
=4.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total equity is a balance sheet item and equal to total assets less total liabilities of the company. Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


POINT Biopharma Global  (NAS:PNT) Tangible Book per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


POINT Biopharma Global Tangible Book per Share Related Terms

Thank you for viewing the detailed overview of POINT Biopharma Global's Tangible Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


POINT Biopharma Global (POINT Biopharma Global) Business Description

Traded in Other Exchanges
N/A
Address
4850 West 78th Street, Indianapolis, IN, USA, 46268
POINT Biopharma Global Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of radioligand therapies for the treatment of cancer. Its product pipeline includes PNT2002; PNT2004; PNT2003; PNT2001 and others.
Executives
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bridget A Martell director C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Joe A. Mccann director, officer: Chief Executive Officer 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Rajesh Malik director 79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Gerald L. Hogue director 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
David Charles Lubner director C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472